Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $933.14 million. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The companyÂ’s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.
In analysts report shared with investors on 4 January, Paddy Power Betfair (LON:PPB) stock Overweight was maintained by Barclays Capital. They currently have a GBX 9400.00 price target on the stock. Barclays Capital’s price target means a potential upside of 8.33% from the company’s previous stock close.
The stock decreased 0.23% or GBX 20 during the last trading session, reaching GBX 8750. About 26,697 shares traded. Paddy Power Betfair plc (LON:PPB) has 0.00% since January 4, 2017 and is . It has underperformed by 16.70% the S&P500.
Paddy Power Betfair plc, together with its subsidiaries, provides online interactive sports betting services in the United Kingdom, Ireland, Australia, the Unites States, and internationally. The company has market cap of 7.52 billion GBP. The firm operates through Online, Australia, Retail, and US divisions. It has a 55.7 P/E ratio. It offers exchange sports betting and pari-mutuel betting products, fixed odds games betting, online games and casino, and business-to-business services, as well as peer to peer games, including online bingo and poker.
Among 20 analysts covering (LON:PPB), 9 have Buy rating, 3 Sell and 8 Hold. Therefore 45% are positive. has GBX 11500 highest and GBX 115 lowest target. GBX 8689.41’s average target is -0.69% below currents GBX 8750 stock price. had 86 analyst reports since February 2, 2016 according to SRatingsIntel. The company was maintained on Tuesday, November 8 by HSBC. The stock of Paddy Power Betfair plc (LON:PPB) earned “Buy” rating by Deutsche Bank on Thursday, August 31. As per Tuesday, April 26, the company rating was upgraded by Morgan Stanley. The rating was maintained by Liberum Capital on Friday, November 4 with “Hold”. The firm earned “Buy” rating on Tuesday, August 8 by Peel Hunt. Barclays Capital maintained the shares of PPB in report on Monday, March 27 with “Overweight” rating. Shore Capital maintained the shares of PPB in report on Monday, January 23 with “Hold” rating. The company was downgraded on Tuesday, September 5 by Morgan Stanley. Barclays Capital maintained Paddy Power Betfair plc (LON:PPB) rating on Monday, April 11. Barclays Capital has “Overweight” rating and GBX 11500 target. The company was maintained on Wednesday, February 3 by Barclays Capital.
The stock increased 5.65% or $1.27 during the last trading session, reaching $23.74. About 503,633 shares traded or 119.21% up from the average. Retrophin, Inc. (RTRX) has risen 4.93% since January 4, 2017 and is uptrending. It has underperformed by 11.77% the S&P500.
Analysts await Retrophin, Inc. (NASDAQ:RTRX) to report earnings on March, 7. After $-0.46 actual EPS reported by Retrophin, Inc. for the previous quarter, Wall Street now forecasts -56.52% EPS growth.
Consonance Capital Management Lp holds 9.65% of its portfolio in Retrophin, Inc. for 3.51 million shares. Broadfin Capital Llc owns 1.72 million shares or 6.32% of their US portfolio. Moreover, Perceptive Advisors Llc has 2.55% invested in the company for 2.69 million shares. The Georgia-based Emory University has invested 1.46% in the stock. Oak Ridge Investments Llc, a Illinois-based fund reported 739,462 shares.